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Abstract
Introduction: In this study, we determined: (1) the utility of an untimed sample of urine protein/creatinine ratio
(PCR) as a screening test for proteinuria, (2) its ability to accurately measure proteinuria, and (3) cutoff values for
PCR predicting protein content in a 24-h urine collection sample (24hP) of 0.5, 1.0, and 2.0 g/day.
Methods: Analysis was performed on data from a single lupus cohort (2008–2014). Proteinuria was measured in a
24hP and with PCR. On the basis of 24hP, samples were divided into 4 groups: group 1, <0.5 g/day; group 2, 0.5–
0.99 g/day; group 3, 1–1.99 g/day; and group 4, ≥2 g/day. To determine the validity of PCR in screening for
proteinuria, the Pearson correlation coefficient was determined for the urine samples with normal PCR (<0.05 g/
mmol) and normal 24hP (<0.5 g/day). The sensitivity, specificity, positive predictive value (PPV), and negative
predictive value (NPV) of PCR were calculated. To determine the ability of PCR to accurately measure the level of
proteinuria, in addition to the correlation between 24hP and PCR, agreement was determined by intraclass
correlation coefficient, concordance correlation coefficient, and Bland-Altman plot between 24hP/24hC and PCR.
The best cutoffs for PCR predicting a 24hP of 0.5, 1.0, and 2.0 g/day were determined with the receiver operating
characteristic curve.
Results: The correlation of the samples with normal PCR as well as 24hP (n = 552) was 0.29 (p < 0.0001). PCR
sensitivity and specificity against 24hP were 91 % and 83 %, respectively. The PPV was 82.5 %, and the NPV was
91.4 %. The correlation for all samples (n = 1233) was high, but low to moderate for groups 1, 2, 3, and 4. The
agreement for all samples was appropriate but poor for groups 1, 2, 3, and 4. PCR cutoffs for 24hP of 0.5, 1.0, and
2.0 g/day were 0.08, 0.16, and 0.35 g/mmol, respectively.
Conclusions: PCR can be used as a screening test for proteinuria, and the best cutoff value to predict a 24hP of
0.5 g/day is 0.08 g/mmol (800 mg/g). The accurate level of proteinuria should be measured by the gold standard
test, 24hP.
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Introduction
Lupus nephritis (LN) is an immune complex glomerulo-
nephritis with a cumulative incidence of 54 % [1]. LN can
occur early (50 %) as well as years after the diagnosis of
systemic lupus erythematosus (SLE) is made (45 %) [2].
The manifestations of renal involvement can be diverse,
including proteinuria and active urinary sediment [3, 4].
Proteinuria is the most common manifestation of LN, be-
ing reported in almost 100 % of patients with LN, followed
by granular casts, cellular casts, hematuria, and reduced
renal function [1, 5]. Proteinuria is the principal urinary
biomarker for the screening of LN [5, 6] and for monitor-
ing disease progression [7–9]. Among the methods for
quantification of the proteinuria, the protein content in a
24-h urine collection sample (24hP) has been considered
the “gold standard,” but this test is cumbersome for patients
and sometimes is collected incorrectly [10]. Ginsberg et al.
proposed using the untimed sample of urine protein/cre-
atinine ratio (PCR) instead of the 24hP [11]. Several authors
have shown a good correlation between PCR and 24hP in
diabetes [12], LN [13, 14], and chronic kidney disease [15].
The American College of Rheumatology (ACR) recom-
mends the PCR for use in clinical trials of LN [16], and the
European League Against Rheumatism recommendations
for the management of adult and pediatric LN suggest
using the first morning PCR as a valid measure of protein-
uria [17]. Nevertheless, other studies have shown a weak
agreement between PCR and 24hP results [18–20]. Clearly,
there is no agreement between the existing studies on the
utility of PCR. The variance of the results of the published
studies is partly related to the method of collection of PCR
and the use of inappropriate statistical analyses in various
studies. The aim of this study was to determine (1) the util-
ity of the spot urine protein/creatinine ratio as a screening
test for proteinuria in patients with SLE, (2) the ability of
PCR to accurately measure the level of proteinuria, and (3)





All adult (≥18 years old) patients with lupus at the
University of Toronto Lupus Clinic at the Toronto Western
Hospital who fulfilled at least four of the ACR revised cri-
teria for the classification of SLE [21] or who met three cri-
teria and had a typical biopsy lesion of SLE were studied.
Inclusion criteria
All patients’ results available in the data collected from
May 2008 until December 2014 were screened for inclu-
sion in this study. Patient visits with proteinuria assess-
ment documented by PCR and 24hP, with both tests being
done within 4 days, were identified and analyzed.
Exclusion criteria
We excluded (1) patients with estimated glomerular filtra-
tion rate (GFR) or creatinine clearance (calculated from
the 24-h urine collection) <15 ml/min, (2) patients on dia-
lysis, (3) patients with proteinuria not related to LN (e.g.,
diabetes mellitus, chronic sclerosing LN, and others), and
(4) patients with kidney transplantation. The majority
(>90 %) of urine specimens were handled and interpreted
at one laboratory, and the appropriate measurements of
preservation and shipment of the urine samples were
applied.
Assessment of patients and measurement of proteinuria
We conducted a retrospective analysis of data collected
prospectively from May 2008 to December 2014. Patients
were attending the lupus clinic at 2- to 6-month intervals
regardless of the activity of their disease. Patients’ assess-
ments include complete history, physical examination,
information about drug treatment, and laboratory exami-
nations. For this study, the laboratory results including
GFR and serum creatinine were analyzed. The PCR sam-
ples were taken the day of the follow-up visit in the clinic
(between 9:00 AM and 5:00 PM), and the results were
reviewed. If PCR was abnormal (>0.05 g/mmol), patients
are contacted and instructed to collect a 24-h urine sam-
ple starting the next day. The 24-h urine sample and PCR
were also collected at follow-up visits for all patients with
proteinuria to check on the response to therapy. The 24-h
urine samples were collected as follows: Patients were
instructed to empty the bladder in the morning and dis-
card the urine, and from that point onward for 24 h, all
urine was to be saved in the container. At the end of that
24-h period, the bladder was emptied, and that urine was
saved.
The collection, storage, and use of the clinical and la-
boratory data on the patients at the center were conducted
in accordance with the Declaration of Helsinki and were
approved by the Research Ethics Board of the University
Health Network, Toronto, ON, Canada. All patients signed
an informed consent form before participation.
Adequacy of urine collection
The adequacy of the 24-h urine sample was assessed by
comparing the creatinine from the 24-h urine sample col-
lection (24hC) with the expected creatinine content (ExC)
using the following the formula: ExC = 28 − (0.2 × age) ×
weight (kg) in men and 23.8− (0.17 × age) × weight in
women [22]. A stratification for ExC by ethnicity was per-
formed because it is likely that the amount of ExC varies by
ethnicity in addition to body weight and/or muscle mass.
Undercollection was defined as a ratio of (ExC − 24hC)/
ExC >0.2, and those samples were excluded [20, 23].
GFR was calculated using the Chronic Kidney Disease
Epidemiology Collaboration equation [24]. Patients were
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also screened to ensure they were not taking any drugs
that would affect the creatinine clearance, such as
trimethoprim.
Definitions of outcome measures
Proteinuria was defined as ≥0.5 g/24 day, based on the def-
initions of the Systemic Lupus Erythematosus Disease Ac-
tivity Index 2000 (SLEDAI-2K) [25] and the ACR criteria
[21]. In the database, proteinuria is recorded as related or
unrelated to LN activity. If proteinuria is not attributed to
SLE activity, it is not scored as present and does not con-
tribute toward the renal component of SLEDAI-2K. The
urinalysis interpretation is based on a physician’s judgment
and interpretation of available laboratory and pathologic
results of other tests (biopsy, urine culture). The laborator-
ies consider an abnormal PCR to be ≥0.05 g/mmol.
Statistical analysis
The sample size was estimated using normal approxima-
tion [26] and exact methods [27] for design accuracy in
diagnostic tests. The sample size in this study (n = 1233) is
beyond the minimum needed to detect an expected sensi-
tivity (Sn) of 0.90 and using a minimal accepted Sn of 0.85
(n = 400 by exact method). Patients’ baseline characteris-
tics at the first pair of 24hP and PCR measurements
[mean ± standard deviation (SD)] and count (%) were used
for continuous and categorical variables, respectively.
Samples were divided into four groups according to
protein excretion over 24 h: group 1, >0.5 g/day;
group 2, 0.5–0.99 g/day; group 3, 1–1.99 g/day; and group
4, ≥2 g/day.
Validity of PCR in screening for proteinuria
The Pearson correlation coefficient was determined for
the urine samples with normal PCR (<0.05 g/mmol) and
normal 24hP (<0.5 g/day). The Sn, specificity (Sp), positive
predictive value (PPV), negative predictive value (NPV),
and positive likelihood ratio (LR+) of PCR were calculated,
and in this analysis 24hP was considered the external
construct. The cutoff for PCR was ≥0.05 g/mmol, and
the cutoff for 24hP was ≥0.5 g/day.
Correlation
The Pearson correlation coefficient was determined for
PCR and 24hP for all urine samples overall and for the
four groups. Correlations were interpreted as follows [28]:
0.00–0.29 = negligible, 0.3–0.49 = low, 0.5–0.7 =moderate,
0.7–0.9 = high, and 0.9–0.99 = very high.
Agreement
The magnitude of the scales 24hP (g/day) and PCR
(g/mmol) is different where 24hP is approximately 7.6
times greater than PCR. Thus, before deriving the agree-
ment between 24hP and PCR, it was essential to adjust for
this difference in both scales. For this purpose, the ratio of
24hP and 24hC reported in a 24-h urine sample (24hP/
24hC content) was calculated. In the following analyses,
we compared 24hP/24hC and PCR.
Intraclass correlation coefficient (ICC) (2, k) [29], con-
cordance correlation coefficient (CCC) [30], and the
Bland-Altman plot [31] for PCR and 24hP/24hC were
determined. ICC describes the associations and agreement
among units in the same group [32]. For the ICC (2, k)
the first number, 2, designates the model, and k signifies
the mean of several measurements as the unit of analysis
[29, 33]. The results of the ICC (2, k) were derived after
applying square root transformation of the data. ICC (2, 1)
was determined in the stratification analysis by ethnicity.
The second number, 1 [ICC (2, 1)], signifies that ICC is
calculated using a single measurement 1. ICC ≥0.85 re-
flects good agreement [34]. The CCC measures the degree
to which paired samples fall in the 45-degree line through
the origin, being of interest for equivalence of new labora-
tory methods with the gold standard [30, 35]. CCC <0.9
was considered poor [35]. The Bland-Altman plot pro-
vides a visual approach to the data whereby the mean and
the difference of PCR and 24hP/24hC were represented
and the limits of agreement (±2 SD) were plotted.
Determination of the best cutoff values for PCR predicting
24hP of 0.5, 1, and 2 g/day
Two different approaches were used: (1) the best cutoff
determined based on a 2 × 2 contingency table (with
24hP considered the gold standard test) and (2) logistic
regression analysis. Continuous values of PCR were fed
into the model as independent variables, and binary high
and low 24hP cutoffs of 0.5, 1.0, or 2.0 were used as
dependent variables. The best cutoffs were determined
based on the analysis of the receiver operating character-
istic (ROC) curve.
Sensitivity analysis
We conducted a separate analysis of patients taking and
those not taking angiotensin-converting enzyme (ACE)
inhibitors and/or angiotensin receptor blockers (ARBs)
p values <0.05 were defined as statistically significant.
The Excel 2010 (Microsoft, Redmond, WA, USA) and
SAS 9.3 (SAS Institute, Cary, NC, USA) software pro-
grams were used for statistical data analysis.
Results
Patient characteristics
A total of 1730 laboratory urine samples from 421 patients
were identified. Of these, 497 samples were excluded
because of undercollection in 24-h urine samples, and 1233
urine samples from 322 patients included in the final ana-
lysis. The ExC values stratified by ethnicity were as follows:
white 17.3 ± 2.8 mmol/day, black 17.5 ± 2.2 mmol/day,
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Asian 17.6 ± 2.6 mmol/day, and other 17.5 ± 2.6 mmol/day.
The patients’ demographics are presented in Table 1. The
majority of the patients were women (83.5 %) with lupus
disease duration of 11.76 ± 9.71 years and age at first 24hP
of 40.26 ± 14.76 years. The number of patients in groups 1,
2, 3, and 4 were 208, 42, 29, and 43, respectively. Eight pa-
tients (2.5 %) were treated with cyclosporine, three (1.4 %)
in group 1, one (2.4 %) in group 2, one (3.4 %) in group 3,
and three (7 %) in the group 4. No patients were treated
with tacrolimus.
Validity of PCR in screening for proteinuria
Of the 1233 urine samples, 552 samples had normal
PCR and 24hP. The Pearson correlation coefficient was
0.29 (p < 0.0001). PCR Sn and Sp against 24hP were 91 %
and 83 %, respectively. PPV was 82.5 %, NPV was 91.4,
and LR+ was 5.4.
Correlation between PCR and 24hP
For all samples (n = 1233), the correlation was high (r =
0.79) (Fig. 1). However, the correlation was low for
group 1 (r = 0.4), negligible for group 2 (r = 0.2), low for
group 3 (r = 0.3), and moderate for group 4 was (r = 0.6)
(all p < 0.05) (Table 2). The correlations of both tests
stratified by ethnicity were high for all ethnic groups
(white 0.76, black 0.86, Asian 0.78, other ethnicities 0.88;
all p < 0.0001).
Agreement between PCR and 24hP/24hC
Intraclass correlation coefficients (2, k)
For all urine samples, ICC was 0.87; for group 1, ICC was
0.52; for group 2, ICC was 0.57; for group 3, ICC was 0.73;
and for group 4, ICC was 0.77. The agreement was appro-
priate for all the urine samples; however, it was poor
(<0.85) for groups 1, 2, 3, and 4 (Table 2), indicating less
than appropriate agreement of paired urine samples in the
same group and poor reproducibility of the measures for
each group.
Concordance correlation coefficients
For all urine samples, CCC was 0.85; for groups 1, 2, 3 and
4, CCCs were 0.62, 0.34, 0.55, and 0.44, respectively. The
agreement was poor (<0.9) for all urine samples and for
groups 1, 2, 3, and 4 (Table 2), indicating that the PCR
levels were not equivalent to the corresponding 24hP levels
in the same patient. The CCC results stratified by ethnicity
were as follows: white 0.69 (95 % CI 0.65–0.74), black 0.94
(95 % CI 0.92–0.96), Asian 0.73 (95 % CI 0.63–0.82), and
other ethnicities 0.69 (95 % CI 0.60–0.77).
Bland-Altman plot
The Bland-Altman plot showed that all the paired urine
samples from group 1 were between the limits of agree-
ment; however, with increases in 24hP values, a large differ-
ence between the two methods was found that was more
obvious in groups 3 and 4 than in the other groups. In
group 4, PCR tended to overestimate the 24hP results. On
the Bland-Altman plot, the dots corresponding to groups 3
and 4 are outside 2 SD, signifying poor agreement (Fig. 2).
Cutoff of PCR predicting a 24hP of 0.5, 1 and 2 g/day
The contingency table, using 24hP of 0.5 g/day as the gold
standard and PCR of 0.05 g/mmol as the index test,
showed Sn and Sp values of 91 % and 83 %, respectively.
The results of the ROC curve derived from the logistic re-
gression showed that a PCR of 0.08 g/mmol (800 mg/g)
reflected 24hP of 0.5 g/day, with Sn of 91 % and Sp of
80 % (Table 3). The overall area under the curve was 0.92
(Fig. 3). For the 24hP cutoffs of 1.0 and 2.0 g/day, the ana-
lyses showed PCR values of 0.16 g/mmol (1600 mg/g; Sn
Table 1 Demographic characteristics of the patients included in the study
Characteristics 24hP <0.5 g/day 24hP 0.5–0.99 g/day 24hP 1–1.99 g/day 24hP ≥2.0 g/day Total
Number of samples (%) 662 (53.7 %) 266 (21.6 %) 171 (13.9 %) 174 (14.1 %) 1233 (100 %)
Number of patients (%) 208 (64.6 %) 42 (13.0 %) 29 (9 %) 43 (13.3 %) 322 (100 %)
Females, n (%) 177 (85.1 %) 32 (76.2 %) 23 (79.3 %) 37 (86.0 %) 269 (83.5 %)
Males, n (%) 31 (14.9 %) 10 (23.8 %) 6 (20.7 %) 6 (14.0 %) 53 (16.5 %)
Whites, n (%) 118 (56.7 %) 23 (54.8 %) 11 (37.9 %) 21 (48.8 %) 173 (53.7 %)
Blacks, n (%) 37 (17.8 %) 7 (16.7 %) 6 (20.7 %) 12 (27.9 %) 62 (19.3 %)
Asians, n (%) 21 (10.1 %) 6 (14.3 %) 5 (17.2 %) 4 (9.3 %) 36 (11.2 %)
Other ethnicities, n (%) 32 (15.4 %) 6 (14.3 %) 7 (24.1 %) 6 (14.0 %) 51 (15.8 %)
Disease duration, yr (SD) 13.02 ± 10.38 8.90 ± 6.23 11.54 ± 9.49 8.61 ± 8.07 11.76 ± 9.71
Age at first 24hP, yr (SD) 42.26 ± 14.88 37.02 ± 16.14 38.33 ± 13.66 35.05 ± 11.58 40.26 ± 14.76
Serum creatinine, μmol/L (SD) 84.39 ± 47.30 87.76 ± 42.56 87.76 ± 42.56 80.49 ± 58.02 84.18 ± 47.03
Patients taking prednisone, n (%) 79 (62.7 %) 22 (59.5 %) 16 (59.3 %) 31 (77.5 %) 148 (64.3 %)
Patients taking immunosuppressives, n (%) 70 (55.6 %) 25 (67.6 %) 14 (51.9 %) 28 (70.0 %) 137 (59.6 %)
24hP Protein content in a 24-h urine collection sample
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90 % and Sp 83 %) and 0.35 g/mmol (3500 mg/g; Sn 91 %
and Sp 85 %), respectively.
Sensitivity analyses for ACE inhibitors and/or ARB
The results for patients taking ACE inhibitors and/or
ARB showed that, correlation among the 164 patients
taking ACE inhibitors and/or ARB, 624 paired sam-
ples were identified. Although the correlation between
24hP and PCR for all samples was 0.77, in group 1
(n = 288) it was 0.4; in group 2 (n = 129), it was 0.2;
in group 3 (n = 114), it was 0.3; and in group 4 (n = 95), it
was 0.6.
Fig. 1 Scatterplot of correlation between protein content in a 24-h urine collection sample; (24hP) and untimed sample of urine protein/creatinine ratio
for all urine samples. PCR spot urine protein/creatinine ratio
Table 2 Results of correlations between 24hP and PCR and agreement between 24hP/24hC and PCR
Correlation Interpretationa ICC (2, k) Interpretationb CCC Interpretationc
p value 95 % CI 95 % CI
All samples 0.79 High 0.87 Appropriate 0.85 Poor
<0.0001 0.83–0.91 0.83–0.87
24hP 0.4 Low 0.52 Poor 0.62 Poor
<0.5 g/day <0.0001 0.50–0.53 0.56–0.67
24hP 0.2 Negligible 0.57 Poor 0.34 Poor
0.5–0.99 g/day 0.0007 0.55–0.58 0.24–0.46
24hP 0.3 Low 0.73 Poor 0.55 Poor
1–1.99 g/day 0.001 0.70–0.76 0.43–0.68
24hP 0.6 Moderate 0.77 Poor 0.44 Poor
≥2.0 g/day 0.0001 0.70–0.83 0.35–0.53
CCC concordance correlation coefficient, CI confidence interval, 24hC measured creatinine content in a 24-h urine sample collection, 24hP protein content in a 24-h urine
collection sample, ICC intraclass correlation coefficient
The ratio of the protein content and the creatinine content in a 24-h urine collection sample (24hP/24hC) was calculated by dividing 24hP (g/day) by creatinine
content (mmol/day) reported in the results of the same 24 h urine sample
aCorrelation: negligible (r = 0.00–0.29), low (r = 0.3–0.49), moderate (r = 0.5–0.7), high (r = 0.7–0.9), very high (r = 0.9–0.99)
bMeasure of agreement: ICC (2, k) ≥0.85 = good reliability (agreement)
cMeasure of agreement: CCC <0.9 = poor agreement
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For all urine samples, ICC was 0.91; for groups 1, 2, 3,
and 4, ICCs were 0.48, 0.60, 0.64, and 0.84, respectively.
For all samples, CCC was 0.93; for groups 1, 2, 3, and 4,
CCCs were 0.59, 0.25, 0.56, and 0.85, respectively.
For the 24hP cutoffs of 0.5, 1.0, and 2.0 g/day, the ana-
lyses showed PCR values of 0.07 g/mmol (700 mg/g; Sn
91 % and Sp 82 %), 0.11 g/mmol (1100 mg/g; Sn 90 %
and Sp 73 %), and 0.15 g/mmol (1500 mg/g; Sn 90 %
and Sp 79 %), respectively.
The analysis for patients not taking ACE inhibitors and/
or ARBs showed results similar to those for the patients
taking ACE inhibitors and/or ARBs. CCC was 0.54 for all
urine samples overall; for groups 1, 2, 3, and 4, CCCs were
0.54, 0.36, 0.39, and 0.36, respectively.
Discussion
In daily practice, proteinuria in patients with SLE has great
importance for the diagnosis of LN, monitoring of disease
activity, and prognosis [6, 8]. Thus, it is very important to
use the most accurate method for measurement of protein-
uria. 24hP is the gold standard for proteinuria assessment
in LN, but PCR has become a widely accepted method of
measurement of proteinuria in clinical practice, research
settings, and clinical trials [9, 36].
The expected creatinine content for different ethnic
groups was similar in our patients, without abnormal re-
sults for any group. Besides this, whereas the correlation
overall of all the paired urine samples and for the ethnic
groups was high, it decreased for the individual groups,
Fig. 2 Bland-Altman plot for ratios of protein content and creatinine content in 24-h urine collection samples (24H-P/24-H Creatinine) and untimed
samples of urine protein/creatinine ratio (PCR)
Table 3 ROC classification for best PCR cutoffs reflecting 24hP 0.5 g/day using binary 24hP as the gold standard









0.983 65 570 1 597 0.098 0.998 0.138
0.970 66 570 1 596 0.100 0.998 0.128
0.909 66 569 2 596 0.100 0.996 0.108
0.847 552 519 52 110 0.834 0.909 0.098
0.754 579 493 78 83 0.875 0.863 0.088
0.628 604 458 113 58 0.912 0.802 0.078
0.340 634 385 186 28 0.958 0.674 0.058
24hP protein content in a 24-h urine collection sample, PCR untimed sample of urine protein/creatinine ratio, ROC receiver operating characteristic
Boldface type indicates statistically significant values
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especially those with higher levels of proteinuria. It is re-
markable that the correlation was negligible for the 24hP
0.5–0.99 g/day group, in which this amount of protein
excretion should alert the clinician about kidney involve-
ment in the course of SLE. For the groups with higher
levels of proteinuria (24hP 1–1.99 and ≥2.0 g/day),
although the correlations improved, they did not reach a
high threshold, making it difficult to confirm that PCR
can replace 24hP for diagnostic purposes. Leung et al. also
showed a high correlation for all samples, but correlation
dropped with larger levels of proteinuria [20].
Correlation and agreement are two different concepts
for a new test. To replace a gold standard test, the new
test has to demonstrate agreement with the gold standard.
In our study, we used different statistical methods to study
agreement. Although the ICC for all the paired urine sam-
ples was appropriate, it was poor for the four independent
groups. The CCC showed poor agreement for all the sam-
ples and in each of the four groups. The Bland-Altman
plot confirmed the lack of agreement between PCR and
24hP, in particular for proteinuria >1 g/day. These results
support the findings of poor diagnostic performance of
PCR for the studied 24hP groups and emphasize the lim-
ited utility of PCR as a substitute for 24hP.
Salesi et al. found a high correlation between 24hP and
PCR in 74 female patients [37]. Chitalia et al. pointed out
that correlation analysis does not enable a reliable decision
to be made in order to replace one with the other [38].
Bland and Altman noted that the correlation is described
over the entire sample range and may conceal disagree-
ment between two tests at the extreme ranges of the same
sample, and it is possible to have a high correlation with
prediction intervals that may be unacceptably wide [39].
Birmingham et al. studied 64 patients with SLE and
showed a moderate correlation and weak agreement for
samples between 0.5 and 3.0 g/day [18]. Choi et al. studied
102 patients and found poor agreement for the group with
24hP 0.5–3 g/day [13]. Zhang et al. found poor agreement
in a study of 90 samples [23]. Conclusions based on correl-
ation alone supported the substitution of 24hP by PCR,
whereas studies with more appropriate statistical analyses
involving agreement clearly showed a weak agreement
between both tests. Our study, supported by the use of
appropriate statistical analyses, emphases the inadequate
validity of PCR as a surrogate for 24hP.
We calculated the best cutoff of PCR predicting a 24hP
of 0.5, 1, or 2 g/day. To decide on the best combination of
Sn and Sp for a screening test, it is important to consider
the costs and possible harms associated with the test [40].
The ROC curve showed that PCR of 0.08, 0.16, or 0.35 g/
mmol would reflect 24hP of 0.5, 1, or 2 g/day, respectively.
Leung et al. [20] determined the PCR cutoffs for 24hP of
0.5, 1, and 3.5 g/day in 129 samples from 82 patients, and
their results (0.45, 0.7, and 1.85 mg/mg, respectively) were
different from ours. Some of the patients in Leung et al.’s
study did not complete the 24-h urine collection, causing
the Sn and Sp to be underestimated. In our study, all the
paired samples were available, and our sample size was lar-
ger. PCR is a test used for clinical decision-making, but
when the quantification of protein is needed, the 24hP still
is the gold standard.
In the present study, the Sn analyses conducted on
patients maintained on ACE inhibitors and/or ARBs, as
well as on patients not taking ACE inhibitors and/or ARBs,
also showed poor reproducibility of the results for 24hP by
PCR; thus, PCR cannot be substituted for 24hP.
Our study has some limitations. The proteinuria meas-
urement tests (24hP and PCR) were not performed on
the same day. However, in this analysis, both tests were
performed in less than a 4-day period, which is consid-
ered too short to affect the confidence of the proteinuria
measurement. Group 4 had a relatively small sample size
(43 patients with 174 paired urine samples), thus limiting
the generalizability of our findings. However, our sample
size was bigger than the samples in other studies with simi-
lar findings [18]. We conducted a cross-sectional study,
and thus analyses of serial samples are not presented. This
is a very relevant question that needs to be answered in
future studies and may be more suitable in an incident
cohort of patients with lupus.
Conclusions
Clinicians in daily practice managing SLE and LN rely on
the accuracy and validity of laboratory results to make ap-
propriate decisions, such as ordering a kidney biopsy or
initiating and/or modifying treatment for LN based on
Fig. 3 Receiver operating characteristic (ROC) curve for best cutoff of
untimed samples of urine protein/creatinine ratio using binary protein
content in a 24-h urine collection sample (24hP) as the gold standard
(24hP cutoff 0.5 g/day)
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proteinuria level. On the basis of the results of our study,
we conclude that PCR can be used as screening test but
still lacks the performance level of the gold standard test,
24hP, in measuring proteinuria. The importance of this
finding is that clinicians cannot rely on PCR results to
make treatment decisions. PCR can be used as a screening
test in patients with SLE, but every abnormal result should
be confirmed with a 24-h urine collection sample to detect
the precise level of proteinuria.
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